TABLE 2.

Frequencies of the subjects in whom NS3/4A protease inhibitor-resistant variants were detected by direct sequencing at baseline and at the time of reelevation of viral loads^a

Time of variant detection	% (n) by aa positionb:
	36	54	80	155	156	168	170
Baseline	0.4 (1)	3 (7)	22 (55)	0.4 (1)	0.8 (2)	10 (26)	0 (0)
Reelevation of viral load	7 (18)	12 (30)	5 (11)	0.4 (1)	4 (10)	1.2 (3)	0.4 (1)

^aNS3/4A protease inhibitor-resistant variants included V36A/C/M/L/G, T54A/S, Q80K/R/H/G/L, R155K/T/I/M/G/L/S/Q, A156V/T/S/I/G, D168A/V/E/G/N/T/Y/H/I, and V170A (19, 20).

^bThe data represent the percentages (n) of patients in whom NS3/4A protease inhibitor-resistant variants were detected by direct sequencing. Patients who achieved a sustained virological response were said to have no detection of resistant variants by direct sequencing at the time of reelevation of the viral load.